ArticleBMC gastroenterology2025
Development and validation of a nomogram-based risk prediction model for non-alcoholic fatty liver disease (NAFLD): a logistic regression analysis in a physical examination population.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Routine health examination indicators for fatty liver disease risk stratification in adults with thyroid dysfunction: a cross-sectional study of 46,311 individuals.Annals of medicine · 2026Article
- Development of a liver stiffness measurement-based nomogram model to identify early CKD risk in patients with MAFLD.BMC gastroenterology · 2026Article
- Elucidating the therapeutic mechanisms of quercetin in hepatic fibrosis: an integrated metabolomic and transcriptomic analysis.Frontiers in nutrition · 2026Article
- AI-driven diagnostic and prognostic models for metabolic dysfunction-associated steatotic liver disease: insights from clinical, imaging, and multi-omics studies-a scoping review.Frontiers in medicine · 2026Review
- Association Between Thyroid Hormone Sensitivity and Non-Alcoholic Fatty Liver Disease in Individuals with Normal Thyroid Function.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe global prevalence of non-alcoholic fatty liver disease (NAFLD) has reached an alarming 25%, based on recent population-based studies. NAFLD diagnosis primarily relies on imaging methods, which may be invasive, costly, or limited. Existing prediction models, such as the Fatty Liver Index (FLI) and NAFLD Liver Fat Score (NLFS), mainly incorporate metabolic parameters from Western populations and neglect non-metabolic factors, limiting their generalizability. To address these limitations, this study developed a screening model integrating both metabolic and non-metabolic indicators, tailored specifically to diverse populations undergoing routine physical examinations.
methodsA retrospective cohort (N = 6,461, 2024) served to construct and validate the NAFLD prediction model, while an external cohort (N = 2,687, 2023) provided additional validation. NAFLD was confirmed by ultrasound. The primary cohort was randomly divided into training (70%) and internal validation (30%) sets. Initially, 20 candidate variables underwent univariate analysis (p < 0.1), and statistically significant variables (p < 0.05) were selected for the final multivariate logistic regression model. Model performance was assessed using area under the curve (AUC), calibration plots, and decision curve analysis (DCA). Robustness was verified through 10 × 10-fold cross-validation and external validation.
resultsThe final predictive model incorporated 12 predictors (age, sex, body mass index (BMI), uric acid (UA), high-density lipoprotein cholesterol (HDL-C), red blood cell count (RBC), creatinine (Cr), free thyroxine (FT4), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alpha-fetoprotein (AFP), triglyceride-glucose index (TyG)). The model demonstrated excellent discrimination, with a training AUC of 0.909 (95% CI: 0.900-0.919) and internal validation AUC of 0.905 (95% CI: 0.891-0.919). Optimal thresholds were 0.307 in training (sensitivity 78.8%, specificity 86.3%) and 0.205 in validation (sensitivity 88.3%, specificity 77.8%). Calibration was excellent (p = 0.989 training, p = 0.263 validation). DCA indicated substantial net benefits within thresholds from 1 to 98%. External validation confirmed strong model performance regarding discrimination, net benefit, and calibration.
conclusionThis study identified crucial risk factors and constructed a robust NAFLD prediction model suitable for routine physical examination populations, offering clinicians a valuable tool for early disease detection and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.